"Medtronic's Stalled Returns and UnitedHealth's Earnings Expectations: What Investors Should Know"

Medtronic's return on capital employed (ROCE) has remained stagnant over the past five years, indicating a lack of reinvestment and potential growth. With an ROCE of 7.2%, below the industry average of 9.7%, the company is not compounding its earnings and has given away 14% of its stock in the last five years. Unless there are significant changes in ROCE and investment strategies, Medtronic may not be a promising investment for those seeking substantial returns.